Physician profile
Alan C Whitters
NPI 1093778532
$169,512.37
in general payments reported to CMS, 2019-2025
15 companies · $30K in 2025
The $30K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $9,749 · 2021: $31K · 2022: $48K · 2023: $21K · 2024: $16K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Travel and Lodging: $8,387 · Food and Beverage: $3,002 · Consulting Fee: $460 · Education: $6.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,624.00 |
| Travel and Lodging | $8,387.34 |
| Food and Beverage | $3,002.23 |
| Consulting Fee | $460.00 |
| Education | $6.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $70,117.05 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $48,887.36 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $28,488.42 | 2019-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $21,141.11 | 2024-2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $265.73 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $189.80 | 2019-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $162.31 | 2019-2023 | Spravato |
| Allergan, INC. | $58.77 | 2019 | |
| Lundbeck LLC | $47.62 | 2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $43.48 | 2019 | |
| Abbvie INC. | $40.66 | 2022 | |
| Shire North American Group INC | $24.84 | 2019 | |
| Vanda Pharmaceuticals INC. | $19.06 | 2019 | |
| Bausch Health US, LLC | $13.91 | 2019 | |
| Acadia Pharmaceuticals INC | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Whitters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.